Online citations, reference lists, and bibliographies.
← Back to Search

New Treatment Option For Second-Stage African Sleeping Sickness: In Vitro And In Vivo Efficacy Of Aza Analogs Of DB289

T. Wenzler, D. Boykin, M. Ismail, J. Hall, R. Tidwell, R. Brun
Published 2009 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ABSTRACT African sleeping sickness is a fatal parasitic disease, and all drugs currently in use for treatment have strong liabilities. It is essential to find new, effective, and less toxic drugs, ideally with oral application, to control the disease. In this study, the aromatic diamidine DB75 (furamidine) and two aza analogs, DB820 and DB829 (CPD-0801), as well as their methoxyamidine prodrugs and amidoxime metabolites, were evaluated against African trypanosomes. The active parent diamidines showed similar in vitro profiles against different Trypanosoma brucei strains, melarsoprol- and pentamidine-resistant lines, and a P2 transporter knockout strain (AT1KO), with DB75 as the most trypanocidal molecule. In the T. b. rhodesiense strain STIB900 acute mouse model, the aza analogs DB820 and DB829 demonstrated activities superior to that of DB75. The aza prodrugs DB844 and DB868, as well as two metabolites of DB844, were orally more potent in the T. b. brucei strain GVR35 mouse central nervous system (CNS) model than DB289 (pafuramidine maleate). Unexpectedly, the parent diamidine DB829 showed high activity in the mouse CNS model by the intraperitoneal route. In conclusion, DB868 with oral and DB829 with parenteral application are potential candidates for further development of a second-stage African sleeping sickness drug.
This paper references
10.1016/j.biochi.2008.02.017
Antiparasitic compounds that target DNA.
W. Wilson (2008)
10.1016/j.actatropica.2008.07.006
Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis.
J. Thuita (2008)
10.1021/JM030604O
O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection.
J. Ansede (2004)
10.1016/J.IJPARA.2007.05.007
Melarsoprol- and pentamidine-resistant Trypanosoma brucei rhodesiense populations and their cross-resistance.
Sonja C Bernhard (2007)
10.1002/JLCR.817
Synthesis of deuterium‐labelled 6‐[5‐(4‐amidinophenyl)furan‐2‐yl]nicotinamidine and N‐alkoxy‐6‐{5‐[4‐(N‐alkoxyamidino)phenyl]‐ furan‐2‐yl}‐nicotinamidines
M. Ismail (2004)
10.1124/mol.106.024653
Roles for the Trypanosoma brucei P2 Transporter in DB75 Uptake and Resistance
Charlotte A. Lanteri (2006)
10.1002/j.1460-2075.1985.tb03772.x
Cultivation in a semi‐defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense.
T. Baltz (1985)
10.1002/3527601783.CH16
Dicationic DNA Minor Groove Binders as Antimicrobial Agents
R. Tidwell (2004)
Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes.
F. Jennings (1983)
10.1517/13543784.14.8.957
Aromatic diamidines as antiparasitic agents
M. D. Soeiro (2005)
Phase 3 trial of pafuramidine maleate (DB289), a novel, oral drug, for treatment of first stage sleeping sickness: safety and efficacy, abstr
G. Pholig (2008)
10.1128/AAC.00005-07
Diphenyl Furans and Aza Analogs: Effects of Structural Modification on In Vitro Activity, DNA Binding, and Accumulation and Distribution in Trypanosomes
Amanda M Mathis (2007)
10.1124/mol.106.031351
Loss of the High-Affinity Pentamidine Transporter Is Responsible for High Levels of Cross-Resistance between Arsenical and Diamidine Drugs in African Trypanosomes
Daniel J. Bridges (2007)
Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure
N. Maina (2007)
Relapsed parasitaemia following chemotherapy of chronic T. brucei infections in mice and its relation to cerebral trypanosomes.
Jennings Fw (1983)
Phase 3 trial of pafuramidine maleate ( DB 289 ) , a novel , oral drug , for treatment of first stage sleeping sickness : safety and efficacy , abstr . 542 . 57 th Meet
G. Priotto (2008)
10.1016/J.ACTATROPICA.2007.07.007
Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate.
N. Maina (2007)
10.1080/00498250500087671
In vitro metabolism of an orally active O-methyl amidoxime prodrug for the treatment of CNS trypanosomiasis
J. Ansede (2005)
10.1021/JM0302602
Synthesis and antiprotozoal activity of aza-analogues of furamidine.
M. Ismail (2003)
10.1038/sj.bjp.0707354
Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease
M. Barrett (2007)
Epidemiological studies on the animal reservoir of gambiense sleeping sickness. Part II. Parasitological and immunodiagnostic examination of the human population.
P. Felgner (1981)
10.3987/COM-03-9716
Synthesis of metabolites of the prodrug 2, 5-bis(4-O-methoxyamidinophenyl)furan
D. Boykin (2003)
10.1016/S0960-894X(96)00557-4
Anti-pneumocystis activity of bis-amidoximes and bis-o-alkylamidoximes prodrugs
D. Boykin (1996)
10.1016/S0001-706X(97)00079-X
The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro.
B. Räz (1997)
10.1128/AAC.00831-08
Efficacy of the Novel Diamidine Compound 2,5-Bis(4-Amidinophenyl)- Furan-Bis-O-Methlylamidoxime (Pafuramidine, DB289) against Trypanosoma brucei rhodesiense Infection in Vervet Monkeys after Oral Administration
R. Mdachi (2008)
Human African trypanosomiasis (sleeping sickness): epidemiological update.
(2006)
10.1086/522982
Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
G. Priotto (2007)
Cultivation in a semidefined medium of animal infective forms of Trypanosoma brucei
T. Baltz (1985)
10.1016/j.trstmh.2008.09.005
Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
M. Balasegaram (2009)
10.1016/S1471-4922(03)00055-2
Waking up to sleeping sickness.
A. Stich (2003)
10.1371/journal.pmed.0050055
Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next>
P. Simarro (2008)
10.1016/j.actatropica.2008.06.006
Multiple-strain infections of Trypanosoma brucei across Africa.
Oliver Balmer (2008)
10.1002/ana.21429
The continuing problem of human African trypanosomiasis (sleeping sickness)
P. Kennedy (2008)
10.1016/S0140-6736(02)09096-7
Drug development for neglected diseases: a deficient market and a public-health policy failure
P. Trouiller (2002)
10.1371/journal.pntd.0000064
Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series
F. Checchi (2007)
10.1371/journal.pntd.0000225
Pentamidine Dosage: A Base/Salt Confusion
T. Dorlo (2008)
10.1128/EC.2.5.1003-1008.2003
Mechanisms of Arsenical and Diamidine Uptake and Resistance in Trypanosoma brucei
E. Matovu (2003)
10.1086/510534
Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
S. Bisser (2007)
10.1128/AAC.00192-06
Accumulation and Intracellular Distribution of Antitrypanosomal Diamidine Compounds DB75 and DB820 in African Trypanosomes
Amanda M Mathis (2006)



This paper is referenced by
10.4172/2165-7831.1000158
Targeting Protein Arginine Methyltransferase 1 Blocks RBM15-MKL1 Fusion-Initiated Human Stem Cell Transformation
S Jin (2017)
Sickness of Second-Stage African Sleeping Treatment 28DAP010, a Novel Diamidine for Evaluation of In Vivo and In Vitro
M. Wang (2014)
10.1128/AAC.00478-11
In Vitro Efficacy of Dicationic Compounds and Mefloquine Enantiomers against Echinococcus multilocularis Metacestodes
B. Stadelmann (2011)
10.1128/AAC.02356-16
In Vitro, Ex Vivo, and In Vivo Activities of Diamidines against Trypanosoma congolense and Trypanosoma vivax
K. Gillingwater (2017)
10.3390/tropicalmed5010029
New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story
Emily A Dickie (2020)
10.2147/DDDT.S42073
Novel 4-substituted phenyl-2,2′-bichalcophenes and aza-analogs as antibacterial agents: a structural activity relationship
W. A. Hussin (2013)
10.1016/j.pt.2018.08.006
The Long Wait for a New Drug for Human African Trypanosomiasis.
C. H. Baker (2018)
10.1124/jpet.110.177220
Mechanisms Underlying Differences in Systemic Exposure of Structurally Similar Active Metabolites: Comparison of Two Preclinical Hepatic Models
Grace Zhixia Yan (2011)
10.1007/s00436-012-2868-z
Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis
N. Shakya (2012)
10.1016/j.ejmech.2011.01.071
1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis.
Bernadette Bourdin Trunz (2011)
Detection and Mechanistic Comparison of Two Anti- Trypanosomal Diamidines in a Rat Renal Model
R. B. Goldsmith (2011)
Analysis of protein kinases regulating the Trypanosoma brucei cell cycle
Elizabeth Thomas (2015)
10.1016/j.bmcl.2013.12.064
Activity of diimidazoline amides against African trypanosomiasis.
Y. Dong (2014)
Research on regulation of cytokinesis in Trypanosoma brucei
Sophie May (2011)
10.2147/DDDT.S102128
Synthesis, antimicrobial, and antiproliferative activities of substituted phenylfuranylnicotinamidines
M. Youssef (2016)
10.3390/tropicalmed5010014
The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History
Harry P De Koning (2020)
10.1371/journal.pone.0022155
Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In Vivo
D. G. Batista (2011)
10.1016/B978-0-7020-5101-2.00046-7
45 – Human African Trypanosomiasis
C. Burri (2014)
10.1016/S2214-109X(16)30237-6
Seeing beyond 2020: an economic evaluation of contemporary and emerging strategies for elimination of Trypanosoma brucei gambiense.
C. S. Sutherland (2017)
10.1021/np300638f
8,8-dialkyldihydroberberines with potent antiprotozoal activity.
M. M. Endeshaw (2013)
10.1111/pim.12046
Imaging African trypanosomes
L. Maclean (2013)
10.1016/S0140-6736(09)60829-1
Human African trypanosomiasis
R. Brun (2010)
Effects of parasitic infection on the pharmacokinetics and disposition of pentamidine analogs
Claudia N Generaux (2010)
10.1055/s-0030-1250411
Sleeping sickness pathogen (Trypanosoma brucei) and natural products: therapeutic targets and screening systems.
V. Hannaert (2011)
10.1128/AAC.01551-10
Trypanocidal Furamidine Analogues: Influence of Pyridine Nitrogens on Trypanocidal Activity, Transport Kinetics, and Resistance Patterns
Christopher P Ward (2011)
10.2147/DDDT.S66469
Evaluation of the biological activity of novel monocationic fluoroaryl-2,2′-bichalcophenes and their analogues
W. A. Hussin (2014)
10.1016/j.bmc.2010.11.047
Dicationic phenyl-2,2'-bichalcophenes and analogues as antiprotozoal agents.
M. Ismail (2011)
10.1021/jm400508e
Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
D. A. Patrick (2013)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
10.1007/978-3-662-46500-4_32
Infektionen
M. Klein (2015)
10.1016/j.bmc.2013.10.050
Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues.
D. A. Patrick (2014)
10.1007/978-3-7091-1556-5_9
Progress Towards New Treatments for Human African Trypanosomiasis
J. A. García-Salcedo (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar